The concentrations of stem cell growth factor (SCGFβ) and GROα were significantly increased in patients with NAFLD with cirrhosis compared to patients with NAFLD with simple steatosis and healthy controls. This evidence concerns the gene CXCL1 and metabolic dysfunction-associated steatotic liver disease.